The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552211073517
Abstract: Objective Multiple myeloma, a plasma cell neoplasm is the second most common hematological malignancy in the United States. Despite significant advances in treatment armamentarium over the last decade, multiple myeloma remains an incurable malignancy. B-cell… read more here.
Keywords: cell; bcma targeting; myeloma; multiple myeloma ... See more keywords
Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022015526
Abstract: B-cell maturation antigen (BCMA)-targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADC), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a phase 2, multicohort study evaluating… read more here.
Keywords: cilta cel; bcma targeting; bcma; exposure ... See more keywords